• Blog
  • Immunology Drug Market Growth Analysis

    Immunology Drug Market Growth Analysis

    Immunology Drug Market Growth Analysis
    Report code - SR1480 Delivery - 2 Weeks
    Immunology Drug Market Size, Share, Growth, Forecast, & Industry Analysis: 2022-2 See more...

    Market Insights

    The Immunology Drug Market is estimated to grow from USD 92.89 billion in 2021 to USD 160.91 billion by 2028 at a CAGR of around 8.13% during the forecast period.

    Immunology Drug Market Size

    Wish to get a free sample? Register Here

    What is the immune system?

    The immune system is a combination of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies several threats such as viruses, bacteria, and parasites, and distinguishes them from the body's healthy tissues. These drugs aid in curing autoimmune diseases. The drugs also help in killing cancer cells and have become the preferred choice of many

    Immunology Drug Market Report Overview

    Market Size in 2028

    USD 160.91 billion

    Market Size in 2021

    USD 92.89 billion

    Market Growth (2022-2028)

    8.13 CAGR

    Base Year of Study

    2021

    Trend Period

    2016-2020

    Forecast Period

    2022-2028

    Key Players

    Key players operating in the immunology drug market are-

    • Pfizer Inc. (U.S.)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • AbbVie, Inc. (U.S.)
    • Bristol-Myers Squibb Company (U.S.)
    • Merck Sharp & Dohme Corp. (U.S.)
    • Novartis AG (Switzerland)
    • Janssen Global Services, LLC (U.S.)
    • Amgen Inc. (U.S.)
    • Astellas Pharma Inc. (Japan)
    • UCB SA (Belgium)

    Market Dynamics

    The rise in the prevalence rate of various types of cancer and rheumatoid cancer, growing funding from various government & non-government organizations, and increasing government initiatives, are some of the key factors augmenting the immunology drug market growth. Moreover, patients with poor prognoses are further expected to boost the growth of the immunology drug trial evidence reveals which after preparing the immune system to fight against cancer immunology, drug effects last for a long time even after the reduction of the tumor. However, the high cost of these drugs is likely to hamper industry growth.

    COVID-19 Impact

    The COVID-19 outbreak positively influenced the immunology drug market growth. The growing use of immunology drugs in the treatment of COVID-19 infection can be effective in the management of the disease. The pandemic has increased the demand for immunology drugs as people are consuming these products to prevent the transmission of coronavirus across the globe. Hence, several manufacturers are trying to develop new products to keep up with the high demand, thus boosting the market growth.

    To get the full scope of the report, Register Here

    Segment Analysis

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    The market is segmented into the following categories-

    By Drug Type

    • Monoclonal Antibodies (mAb)
    • Antibody Drug Conjugates
    • Interferon and Cytokine therapies
    • Immunosuppressive medication

    By Application Type 

    • Hospitals
    • Clinics
    • Cancer Research Centers and Institutes

    By Region

    • North America
    • Asia-Pacific
    • Europe
    • Rest of the World

    By Drug Type

    The immunology drug market has been classified into monoclonal antibodies (mAb), antibody-drug conjugates, interferon and cytokine therapies, immunosuppressive medication. Under these, the monoclonal antibodies (mAb) segment accounted for a significant market share in 2021 and is projected to register significant growth during the review period. This is mainly attributed to the rising number of approvals for mAb by government bodies to treat chronic ailments across the globe, further fostering segment growth.

    By Region

    The market in North America accounted for a significant market share in 2021 and is projected to grow at a significant CAGR during the assessment period. This is mainly ascribed to the rising prevalence of chronic ailments, robust healthcare infrastructure, the higher diagnosis rate of the patients, increasing healthcare expenditure, and a large number of home healthcare facilities, which further proliferates regional market growth.

    To know which region offers the best growth opportunities, Register Here

    Target Audience

    Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    What deliverables will you get in this report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth analysis of the  Immunology Drug Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional and country level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The immune system is a combination of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies several threats such as viruses, bacteria, and parasites and distinguishes them from the body's healthy tissues. These drugs aid in curing autoimmune diseases. The drugs also help in killing cancer cells and have become the preferred choice of many.

    The immunology drug market is projected to grow from USD 92.89 billion in 2021 to USD 160.91 billion by 2028.

    The immunology drug market is expected to witness an impressive growth of 8.13% CAGR in the coming years.

    Pfizer Inc. (U.S.) F. Hoffmann-La Roche Ltd. (Switzerland) AbbVie, Inc. (U.S.) Bristol-Myers Squibb Company (U.S.) Merck Sharp & Dohme Corp. (U.S.) Novartis AG (Switzerland) Janssen Global Services, LLC (U.S.) Amgen Inc. (U.S.) Astellas Pharma Inc. (Japan) UCB SA (Belgium)

    North America accounted for the largest share in the immunology drug market in 2021.

    The rise in the prevalence rate of various types of cancer and rheumatoid cancer, growing funding from the various government & non-government organizations, and increasing government initiatives, are some of the key factors augmenting the immunology drug market growth. Moreover, patients with poor prognoses are further expected to boost the growth of the immunology drug trial evidence reveals which after preparing the immune system to fight against cancer immunology, drug effects last for a long time even after the reduction of the tumor. However, the high cost of these drugs is likely to hamper industry growth.

    The monoclonal antibodies (mAb) segment accounted for a significant market share in 2021.

    By Drug Type (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication), By Application (Hospitals, Clinics, Cancer Research Centers and Institutes), and Region (North America, APAC, Europe, Rest of the World).